Treating Patients with Acquired TKI Resistance

Treating Patients with Acquired TKI Resistance

ASCO 2016 – Lung Cancer

Benjamin P. Levy, MD, provides an overview of evolving strategies to manage patients with acquired TKI resistance in advanced non–small-cell lung cancer with a focus on identifying and treating t790m.

Related Items

IFCT-1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)-associated advanced non-squamous non-small-cell lung cancer (NS-NSCLC)

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

An open-label phase 2 trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928)

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

E1505: Adjuvant chemotherapy ± bevacizumab for early stage NSCLC—outcomes based on chemotherapy subsets

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer